scholarly article | Q13442814 |
review article | Q7318358 |
P50 | author | Antonio Palumbo | Q87013105 |
Joan Bladé | Q87885218 | ||
Heinz Ludwig | Q89444139 | ||
Torben Plesner | Q92735832 | ||
Sonja Zweegman | Q92858507 | ||
Mario Boccadoro | Q98568600 | ||
Pia Sondergeld | Q114442074 | ||
Jamie D Cavenagh | Q114442098 | ||
Nicolas Ketterer | Q117252291 | ||
Johannes Drach | Q123476050 | ||
Urs Hess | Q123476051 | ||
Martin Kropff | Q123476055 | ||
Hartmut Goldschmidt | Q23061917 | ||
Hermann Einsele | Q1610986 | ||
Jean-Luc Harousseau | Q3167165 | ||
Jesús San Miguel | Q5930658 | ||
Athanasios Dimopoulos | Q26338766 | ||
Ofer Shpilberg | Q28052929 | ||
Meral Beksac | Q57078421 | ||
Michele Cavo | Q57233657 | ||
Gareth J. Morgan | Q61996585 | ||
Larisa Mendeleeva | Q63641376 | ||
Pieter Sonneveld | Q73546936 | ||
Thierry Facon | Q85789960 | ||
P2860 | cites work | Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial | Q28252396 |
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial | Q30433139 | ||
Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma | Q33375805 | ||
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression | Q33376149 | ||
Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy | Q33376181 | ||
Use of bortezomib as induction therapy prior to stem cell transplantation in frontline treatment of multiple myeloma: impact on stem cell harvesting and engraftment | Q33376918 | ||
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma | Q33377526 | ||
Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma. | Q33378895 | ||
Expanding role of bortezomib in multiple myeloma: nursing implications | Q33379476 | ||
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma | Q33380816 | ||
High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program | Q33382175 | ||
Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). | Q33383048 | ||
Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results | Q33384298 | ||
Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma | Q33384668 | ||
Antitumor activity of thalidomide in refractory multiple myeloma | Q33880642 | ||
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma | Q34195428 | ||
Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma | Q34401962 | ||
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America | Q34585268 | ||
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline | Q34603644 | ||
Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. | Q34604658 | ||
VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA s | Q34613164 | ||
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma | Q34815786 | ||
Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation | Q35606328 | ||
Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO). | Q35803516 | ||
Improved survival in multiple myeloma and the impact of novel therapies | Q36478461 | ||
Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma | Q36765107 | ||
Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities | Q36941047 | ||
Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma | Q37007113 | ||
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma | Q37038414 | ||
Thalidomide for treatment of multiple myeloma: 10 years later | Q37075738 | ||
Individualizing treatment of patients with myeloma in the era of novel agents. | Q37143728 | ||
Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone | Q37268930 | ||
Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy | Q37353007 | ||
Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma | Q37375819 | ||
The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network | Q37493951 | ||
Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma | Q37523265 | ||
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens | Q37533983 | ||
The role of complete response in multiple myeloma | Q37564828 | ||
Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma | Q40201943 | ||
VAD-based regimens as primary treatment for multiple myeloma | Q41924796 | ||
Thalidomide maintenance in multiple myeloma: certainties and controversies | Q43273410 | ||
Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma | Q43282882 | ||
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma | Q43726973 | ||
The role of second autografts in the management of myeloma at first relapse. | Q44204181 | ||
An update of the management of multiple myeloma: the changing landscape | Q44248081 | ||
Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure | Q44620764 | ||
Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis | Q44738504 | ||
Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure | Q44971622 | ||
Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function | Q45250378 | ||
Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. | Q46006794 | ||
Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. | Q46068547 | ||
Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure | Q46094234 | ||
Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival | Q46253134 | ||
Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma | Q46291462 | ||
Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study | Q46423653 | ||
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. | Q46573449 | ||
Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. | Q46793597 | ||
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study | Q46804697 | ||
Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma | Q46827259 | ||
Should prophylactic granulocyte-colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy? | Q46859906 | ||
Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis | Q46936772 | ||
Recent major improvement in long-term survival of younger patients with multiple myeloma | Q46977305 | ||
Thalidomide and hematopoietic-cell transplantation for multiple myeloma | Q46981475 | ||
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial | Q46985882 | ||
Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft? | Q48011772 | ||
Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion. | Q53589005 | ||
A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy | Q58050810 | ||
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome | Q71123629 | ||
Tubular NF-kappaB and AP-1 activation in human proteinuric renal disease | Q74566827 | ||
Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients | Q78102288 | ||
Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials | Q79345406 | ||
Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease | Q79420311 | ||
Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield | Q80008483 | ||
Maintenance therapy with thalidomide improves survival in patients with multiple myeloma | Q80011690 | ||
The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone | Q80667422 | ||
Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma | Q80764931 | ||
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial | Q80776203 | ||
Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma | Q80984355 | ||
Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma | Q81251723 | ||
Prolonged overall survival with second on-demand autologous transplant in multiple myeloma | Q83300465 | ||
P433 | issue | 1 | |
P921 | main subject | thalidomide | Q203174 |
boronic acid | Q335768 | ||
multiple myeloma | Q467635 | ||
antineoplastic | Q2853144 | ||
pyrazine | Q47463389 | ||
P1104 | number of pages | 20 | |
P304 | page(s) | 6-25 | |
P577 | publication date | 2010-01-19 | |
P1433 | published in | Oncologist | Q2122327 |
P1476 | title | Current multiple myeloma treatment strategies with novel agents: a European perspective | |
P478 | volume | 15 |
Q38139989 | An old drug with a new future: bendamustine in multiple myeloma. |
Q42184785 | Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma without Cryopreservation |
Q37197900 | BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice |
Q55058300 | Bortezomib-cyclophosphamide-dexamethasone (VCD) versus bortezomib-thalidomide-dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis. |
Q33874209 | Case report on renal failure reversal in lambda chain multiple myeloma with bortezomib and dexamethasone |
Q55515927 | Characteristics and outcomes of patients with multiple myeloma : Data from a developing country. |
Q90266389 | Chicken or Egg: Is Clonal Hematopoiesis Primarily Caused by Genetic or Epigenetic Aberrations? |
Q83979410 | Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone |
Q26795696 | Clinical characteristics of patients with relapsed multiple myeloma |
Q37761370 | Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. |
Q38271032 | Current treatment landscape for relapsed and/or refractory multiple myeloma |
Q31094748 | Design and rationale of FOCUS (PX-171-011): a randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM) |
Q36254820 | Diagnostic and therapeutic approaches to multiple myeloma patients: 'Real-world' data from representative multicentre treatment surveys in Germany between 2008 and 2011. |
Q55383806 | Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma. |
Q38037600 | Emerging biological insights and novel treatment strategies in multiple myeloma |
Q35989943 | European perspective on multiple myeloma treatment strategies: update following recent congresses |
Q85084727 | Guest editorial: understanding the pathogenesis and the evolving treatment paradigm for multiple myeloma in the era of novel agents |
Q55310900 | Impaired efferocytosis by monocytes in multiple myeloma. |
Q38199171 | Is high cut-off hemodialysis effective in myeloma kidney? |
Q37978343 | Management of myeloma-associated renal dysfunction in the era of novel therapies |
Q38888980 | Modulation of cereblon levels by anti-myeloma agents. |
Q37858327 | Multiple myeloma treatment strategies with novel agents in 2011: a European perspective |
Q34420112 | Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone |
Q38108391 | Perspectives in the treatment of multiple myeloma |
Q33938595 | Platelet factor-4 and its p17-70 peptide inhibit myeloma proliferation and angiogenesis in vivo |
Q30802505 | Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data |
Q39583526 | Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma |
Q43115406 | Renal recovery with lenalidomide in a patient with bortezomib-resistant multiple myeloma |
Q30501430 | Shear flow-induced formation of tubular cell protrusions in multiple myeloma cells. |
Q40621650 | Stem cell mobilization chemotherapy with gemcitabine is effective and safe in myeloma patients with bortezomib-induced neurotoxicity |
Q40647620 | Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomide |
Q34081748 | Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines |
Q34227679 | The small heat shock protein B8 (HSPB8) confers resistance to bortezomib by promoting autophagic removal of misfolded proteins in multiple myeloma cells. |
Q30538040 | Time-dependent endpoints as predictors of overall survival in multiple myeloma |
Q92930272 | Unplanned admissions for patients with myeloma in the UK: Low frequency but high costs |
Search more.